EYECARE Glaukos Announces Second Quarter 2023 Financial Results By Staff Monday, August 7, 2023 12:15 AM ALISO VIEJO, Calif.—Glaukos Corp. (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced financial results for the second quarter ended June 30, 2023. Net sales of $80.4 million in Q2 2023 increased 11 percent year-over-year. Glaucoma net sales of $61.9 million in Q2 2023 increased 10 percent year-over-year while corneal health net sales of $18.5 million in Q2 2023 increased 11 percent year-over-year.The company also raised its 2023 net sales guidance to $304 million to $308 million, compared to $295 million to $300 million previously. “Our record second quarter results highlighted by double-digit topline growth reflect the successful execution of our commercial strategies thus far in 2023,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to prudently invest in and advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”GAAP and non-GAAP research and development (R&D) expenses for the second quarter of 2023 increased 5 percent to $33.2 million, compared to $31.7 million in the same period in 2022.Loss from operations in the second quarter of 2023 was $29.1 million, compared to operating loss of $36.8 million in the second quarter of 2022. Non-GAAP loss from operations in the second quarter of 2023 was $22.8 million, compared to non-GAAP operating loss of $30.4 million in the second quarter of 2022.Net loss in the second quarter of 2023 was $32.8 million compared to net loss of $45.5 million in the second quarter of 2022. Non-GAAP net loss in the second quarter of 2023 was $26.6 million compared to non-GAAP net loss of $39.1 million in the second quarter of 2022.Included in non-GAAP loss from operations, non-GAAP net loss and non-GAAP EPS for the second quarter of 2023 and 2022 are acquired in-process R&D (IPR&D) charges of $3.0 million and $10.0 million, respectively.The company ended the second quarter of 2023 with approximately $310 million in cash and cash equivalents, short-term investments and restricted cash.Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.